109 related articles for article (PubMed ID: 18516018)
21. Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.
Di Salvo A; Fabiano C; Mannara V; Dimarco M; Orlando A; Affronti M; Macaluso FS; Cottone M
Dig Liver Dis; 2016 Dec; 48(12):1506-1509. PubMed ID: 27665263
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
Tajiri H; Tomomasa T; Yoden A; Konno M; Sasaki M; Maisawa S; Sumazaki R; Shimizu T; Toyoda S; Etani Y; Nakacho M; Ushijima K; Kobayashi A;
Digestion; 2008; 77(3-4):150-4. PubMed ID: 18577852
[TBL] [Abstract][Full Text] [Related]
23. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
Gupta P; Gokhale R; Kirschner BS
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
[TBL] [Abstract][Full Text] [Related]
24. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists.
Wallace TM; Veldhuyzen van Zanten SJ
Can J Gastroenterol; 2001 Jan; 15(1):21-8. PubMed ID: 11173323
[TBL] [Abstract][Full Text] [Related]
25. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
Rogler G
Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
[No Abstract] [Full Text] [Related]
26. Position statement: immunomodulator therapy for inflammatory Bowel disease.
Lavy A; Chowers Y; Odes HS; Eliakim R;
Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
[No Abstract] [Full Text] [Related]
27. [Better therapeutic potential for azathioprine and mercaptopurine].
Bergan S; Norge O
Lakartidningen; 2000 Apr; 97(16):1999-2000. PubMed ID: 10826362
[No Abstract] [Full Text] [Related]
28. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
[TBL] [Abstract][Full Text] [Related]
29. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
[TBL] [Abstract][Full Text] [Related]
30. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.
Gardiner SJ; Begg EJ; Barclay ML; Kirkpatrick CM
Adverse Drug React Toxicol Rev; 2000 Dec; 19(4):293-312. PubMed ID: 11212460
[No Abstract] [Full Text] [Related]
32. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
33. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
34. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
Min MX; Weinberg DI; McCabe RP
J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
[TBL] [Abstract][Full Text] [Related]
35. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression.
Allorge D; Hamdan R; Broly F; Libersa C; Colombel JF
Gut; 2005 Apr; 54(4):565. PubMed ID: 15753546
[No Abstract] [Full Text] [Related]
36. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
37. [Crohn's disease: no advantage by azathioprine and 6-mercaptopurine].
Schreiber S
Dtsch Med Wochenschr; 2013 Sep; 138(38):1877. PubMed ID: 24022448
[No Abstract] [Full Text] [Related]
38. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
39. A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain.
Egan LJ
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):170-1. PubMed ID: 17296527
[No Abstract] [Full Text] [Related]
40. [Immunomodulator: azathioprine and 6-mercaptopurine].
Suzuki K; Honda Y; Kawauchi Y; Yokoyama J
Nihon Rinsho; 2012 Feb; 70 Suppl 1():318-23. PubMed ID: 23126110
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
